HeH-MZhengSChenY, et al.A comparison of the prognostic ability of liver fibrosis scores in AMI patients with and without type 2 diabetes. Angiology2024;75:219-230.
2.
BoutariCMantzorosCS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism2022;133:155217.
3.
MullishBHForlanoRManousouPMikhailidisDP. Non-alcoholic fatty liver disease and cardiovascular risk: an update. Expert Rev Gastroenterol Hepatol2018;12:1175-1177.
4.
RinellaMELazarusJVRatziuV, et al.A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol2023;79:1542-1556.
5.
KokkorakisMBoutariCKatsikiNMantzorosCS. From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need. Metabolism2023;147:155664.
6.
MazidiMKatsikiNMikhailidisDPBanachM. Ideal cardiovascular health associated with fatty liver: results from a multi-ethnic survey. Atherosclerosis2019;284:129-135.
7.
KatsikiNPerez-MartinezPAnagnostisPMikhailidisDPKaragiannisA. Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome?Curr Vasc Pharmacol2017;16:219-227.
8.
KatsikiNAthyrosGVMikhailidis DP. Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: an underestimated predictor of vascular risk?Curr Vasc Pharmacol2016;14:432-441.
9.
BoutariCMantzorosCS. Inflammation: a key player linking obesity with malignancies. Metabolism2018;81:A3–A6.
10.
MuzurovićEPengCCHBelangerMJSanoudouDMikhailidisDPMantzorosCS. Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors. Hypertension2022;79:1319-1326.
11.
MuzurovićEMikhailidisDPMantzorosC. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk. Metabolism2021;119:154770.
12.
MózesFELeeJASelvarajEA, et al.Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut2022;71:1006-1019.
13.
GoyaleAJainASmithC, et al.Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. PLoS One2021;16:e0260313.
14.
CusiKIsaacsSBarbD, et al.American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract2022;28:528-562.
15.
YounossiZMCoreyKELimJK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. Gastroenterology2021;160:912-918.
16.
StahlEPDhindsaDSLeeSKSandesaraPBChalasaniNPSperlingLS. nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol2019;73:948-963.
17.
ArnettDKBlumenthalRSAlbertMA, et al.2019ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;74:e177-232.
18.
CosentinoFGrantPJAboyansV, et al.2019ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:255-323.
19.
WongVWWongGLYeungJC, et al.Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology2016;63:754-763.
20.
BarattaFPastoriDAngelicoF, et al.Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study. Clin Gastroenterol Hepatol2020;18:2324-2331.
21.
TamakiNKurosakiMTakahashiY, et al.Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. J Gastroenterol Hepatol2021;36:2960-2966.
22.
KatsikiNStoianAPRizzoM. Dietary patterns in non-alcoholic fatty liver disease (NAFLD): stay on the straight and narrow path. Clínica e Investig en Arterioscler2022;34:S24-31.
23.
WahidAManekNNicholsM, et al.Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and Meta-Analysis. J Am Heart Assoc2016;5:e002495.
24.
EslamMSarinSKWongVW, et al.The Asian pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int2020;14:889-919.
25.
Vilar-GomezEMartinez-PerezYCalzadilla-BertotL, et al.Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology2015;149:367-378.
26.
TangADesaiAHamiltonG, et al.Accuracy of MR imaging–estimated proton density fat fraction for classification of dichotomized histologic Steatosis grades in nonalcoholic fatty liver disease. Radiology2015;274:416-425.
27.
SattarNMcGuireDKPavoI, et al.Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med2022;28:591-598.
28.
MantovaniAPetraccaGCsermelyABeatriceGTargherG. Sodium-Glucose Cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Metabolites2021;11:1-11.
29.
RinellaMENeuschwander-TetriBASiddiquiMS, et al.AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology2023;77:1797-1835.
30.
BelfortRHarrisonSABrownK, et al.A placebo-controlled trial of pioglitazone in subjects with nonalcoholic Steatohepatitis. N Engl J Med2006;355:2297-2307.
31.
AthyrosVGAlexandridesTKBilianouH, et al.The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism2017;71:17-32.
32.
AthyrosVGTziomalosKGossiosTD, et al.Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet2010;376:1916-1922.
